about
Turnover-based in vitro selection and evolution of biocatalysts from a fully synthetic antibody library.Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells.The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.KSHV manipulates Notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endotheliaExploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNA.miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator.Kaposi's sarcoma herpesvirus microRNAs induce metabolic transformation of infected cellsKaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.Suppression of AGO2 by miR-132 as a determinant of miRNA-mediated silencing in human primary endothelial cells.Kaposi sarcoma as a model of oncogenesis and cancer treatment.Dissecting the roles of TRBP and PACT in double-stranded RNA recognition and processing of noncoding RNAs.S6K2-mediated regulation of TRBP as a determinant of miRNA expression in human primary lymphatic endothelial cells.microRNAs in the Lymphatic Endothelium: Master Regulators of Lineage Plasticity and Inflammation.The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis.Argonaute Utilization for miRNA Silencing Is Determined by Phosphorylation-Dependent Recruitment of LIM-Domain-Containing Proteins.IL-36γ has proinflammatory effects on human endothelial cells.Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus.Noncoding RNAs and cancer.Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells.A transcriptomic network identified in uninfected macrophages responding to inflammation controls intracellular pathogen survival.Conserved asymmetry underpins homodimerization of Dicer-associated double-stranded RNA-binding proteins.MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasisA HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxiamiR-132 suppresses transcription of ribosomal proteins to promote protective Th1 immunityLong Non-Coding RNA Function in CD4+ T Cells: What We Know and What Next?Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasisMalat1 Suppresses Immunity to Infection through Promoting Expression of Maf and IL-10 in Th CellsImmunobiology and host response to KSHV infection
P50
Q31142518-1123416F-B538-453F-A9DA-90C8B5ECB07EQ33283844-D15D8E1D-52DE-462E-B9D8-427DA2077DC1Q33470219-A48BFE01-78CD-4F36-B722-786036EB8409Q33509506-97D548DB-41C1-406A-9D6F-91A24AC84A64Q34043834-56F619D6-5FCA-4F2C-8B50-7AD884899395Q34112056-461CAA3B-3F00-436B-9DA8-6100FC365234Q34257830-6D1372C6-A117-4F0A-BD03-F4B8DA115366Q34548882-63265AAD-6882-48FA-9EE6-586CCA7FB72EQ36371586-E85BED29-0750-4F60-9F75-EBAFBF206EB3Q36731435-6704B465-BDEF-4EAC-97E9-86BA1A5B3697Q38335714-D52B072D-A645-49F3-A112-60F929A64BA1Q38758450-68092ACF-AF3D-4B80-81A6-45A87ACB2173Q39148619-78029544-EC9E-46B8-98FD-B6969C4746A9Q39255444-EE18A1DE-CF45-405C-A7C5-CB68AB1D2C08Q40145349-8AAA00B0-EDC3-433D-AF89-985EB04081A8Q40526106-250386E6-12C3-4323-845D-1F613644FAF8Q41365661-73B3FE0F-0833-4B94-A23E-A27C46D30AD4Q42108249-07AF5E90-F452-4DBB-A2F8-6C6C34F34C13Q42502875-828138E4-9EAA-4DA4-85F5-679BFEEB4735Q42922864-73F5C1F2-B703-4ABD-A3E3-F4FE46689BCEQ47106289-080D0DAD-8B11-4274-AB72-8F5DE67007A0Q49222124-E62AB4B4-57C5-4CF2-9E28-09A64E2645F6Q58867683-7FE7C425-7548-487E-9DA5-A0F57861BD52Q89181309-41159DC3-B24C-4233-AF3B-AF9C3F338140Q92126524-531792F0-76A4-4C5E-9FD8-378C09306CA4Q92129207-D9987049-3269-4B73-9B2D-E3D171DA9882Q92902263-A75ED775-907E-4566-AB18-AC22EDC1A5A6Q93161692-2DBF64D8-8ED5-4E0F-B3CD-6ABB5F14DBCCQ95459392-FC85A180-D0A6-4A81-AC47-4EEB7816FEB9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dimitris Lagos
@ast
Dimitris Lagos
@en
Dimitris Lagos
@es
Dimitris Lagos
@nl
type
label
Dimitris Lagos
@ast
Dimitris Lagos
@en
Dimitris Lagos
@es
Dimitris Lagos
@nl
prefLabel
Dimitris Lagos
@ast
Dimitris Lagos
@en
Dimitris Lagos
@es
Dimitris Lagos
@nl
P106
P31
P496
0000-0003-0637-281X